ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
07/07/201508:10:03Allergan Buys Rights to Merck's Migraine Drugs
07/07/201508:07:09Allergan Buys Rights to Merck's Migraine Drugs -- Update
07/07/201507:45:44Allergan Buys Rights To Merck's Migraine Drugs
07/07/201507:00:00Allergan Enters Into Licensing Agreement with Merck to Obtain...
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
06/29/201509:27:34Merck Regimen to Reduce Nausea Meets Primary Endpoint
06/29/201508:30:00Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant...
06/29/201508:00:00Sanofi Pasteur and Merck Vaccines Appoint David Khougazian as...
06/26/201508:00:00Merck to Hold Second-Quarter 2015 Sales and Earnings Conference...
06/21/201511:06:03What Is Cancer Immunotherapy?
06/19/201507:58:02Why Bristol-Myers Squibb Co.'s Stock Could Sink
06/18/201516:40:12Annual Report of Employee Stock Plans (11-k)
06/18/201516:37:36Annual Report of Employee Stock Plans (11-k)
06/18/201516:35:51Annual Report of Employee Stock Plans (11-k)
06/17/201517:43:42Inspire Pharmaceuticals Settles Federal Fraud Claims
06/15/201514:50:04EU Approves Merck KGaA $17 Billion Purchase of Sigma-Aldrich

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad